What’s likely to be at the top of investors’ minds during Pfizer’s fourth-quarter conference call Tuesday morning? How about Pfizer’s plans to overcome oncoming competition involving several important products while navigating what remains a difficult pricing environment? Clues from CEO Ian Read and the management team about the company’s capital deployment plans ought to be of high interest, too. In the wake of continued speculation around the sale of its consumer business, which operates as part of its Innovative Health segment and is home to the Chapstick and Advil brands, potential strategic M&A and divestitures could make up for slowing revenue growth seen across existing therapies.